These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17923619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Sorensen PS, Bertolotto A.
    Neurology; 2007 Oct 09; 69(15):1552; author reply 1553. PubMed ID: 17923618
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT.
    Arch Neurol; 2010 Apr 09; 67(4):386-7. PubMed ID: 20385901
    [No Abstract] [Full Text] [Related]

  • 5. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 Sep 02; 71(10):766-73. PubMed ID: 18765653
    [Abstract] [Full Text] [Related]

  • 6. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
    Sorensen PS, Tscherning T, Mathiesen HK, Langkilde AR, Ross C, Ravnborg M, Bendtzen K.
    Neurology; 2006 Nov 14; 67(9):1681-3. PubMed ID: 17101906
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS, European NABINMS Consortium.
    J Int Med Res; 2008 Nov 14; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.
    Neurology; 2007 Mar 27; 68(13):977-84. PubMed ID: 17389300
    [Abstract] [Full Text] [Related]

  • 11. Interferon-beta1b in multiple sclerosis.
    Buttmann M, Rieckmann P.
    Expert Rev Neurother; 2007 Mar 27; 7(3):227-39. PubMed ID: 17341170
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Neurology; 2002 Jan 22; 58(2):169-78. PubMed ID: 11805241
    [No Abstract] [Full Text] [Related]

  • 15. Evidence-based medicine and clinical trials.
    Coyle PK.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S3-7. PubMed ID: 17562847
    [Abstract] [Full Text] [Related]

  • 16. Re: Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Stricker RB, Johnson L.
    Neurology; 2008 May 06; 70(19):1719; author reply 1719-20. PubMed ID: 18458234
    [No Abstract] [Full Text] [Related]

  • 17. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
    Giovannoni G, Goodman A.
    Neurology; 2005 Jul 12; 65(1):6-8. PubMed ID: 16009876
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.